Literature DB >> 1607708

Complement factor 9 deficiency in serum of human neonates.

H A Lassiter1, S W Watson, M L Seifring, J E Tanner.   

Abstract

The serum concentration of complement factor C9 (C9) was 260 +/- 47 micrograms/ml (+/- SE) in 14 mothers and less than 42 micrograms/ml in each of their 14 neonates. During incubation for 60 min, 11 of 14 maternal sera and 3 of 14 neonatal sera reduced the survival of Escherichia coli O7w:K1:NM to less than 20% of the original inoculum (P less than .03). Eleven neonatal sera did not kill the bacteria. Supplemental C9 (60 micrograms/ml) enhanced the bactericidal capacity of 10 neonatal sera. 125I-labeled C9 was deposited onto E. coli by neonatal sera, but less efficiently than by pooled adult sera. Supplemental IgG enhanced 125I-labeled C9 deposition and potentiated the bactericidal activity of exogenous C9. Therefore, neonatal sera contained diminished concentrations of C9 and killed E. coli inefficiently. In neonatal sera, supplemental C9 was deposited onto E. coli and enhanced bactericidal activity. These effects of C9 were potentiated by supplemental IgG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607708     DOI: 10.1093/infdis/166.1.53

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Comparison of three different methods for measuring classical pathway complement activity.

Authors:  T D Jaskowski; T B Martins; C M Litwin; H R Hill
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

2.  Humanized mice, a new model to study the influence of drug treatment on neonatal sepsis.

Authors:  Wolfgang Ernst; Nicole Zimara; Frank Hanses; Daniela N Männel; Birgit Seelbach-Göbel; Anja K Wege
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 3.  Role of innate host defenses in susceptibility to early-onset neonatal sepsis.

Authors:  James L Wynn; Ofer Levy
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

4.  Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15.

Authors:  Flavie Pouillot; Maryline Chomton; Hélène Blois; Celine Courroux; Julien Noelig; Philippe Bidet; Edouard Bingen; Stéphane Bonacorsi
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

Review 5.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells.

Authors:  Ravi Maruvada; Anna M Blom; Nemani V Prasadarao
Journal:  Immunology       Date:  2007-11-20       Impact factor: 7.397

7.  Influence of some bacterial and host factors on colonization and invasiveness of Escherichia coli K1 in neonatal rats.

Authors:  M Wullenweber; L Beutin; S Zimmermann; C Jonas
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 8.  Does inflammation after stroke affect the developing brain differently than adult brain?

Authors:  Zinaida S Vexler; Midori A Yenari
Journal:  Dev Neurosci       Date:  2009-08-11       Impact factor: 2.984

Review 9.  Mechanisms of perinatal arterial ischemic stroke.

Authors:  David Fernández-López; Niranjana Natarajan; Stephen Ashwal; Zinaida S Vexler
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-26       Impact factor: 6.200

Review 10.  The role of inflammation in perinatal brain injury.

Authors:  Henrik Hagberg; Carina Mallard; Donna M Ferriero; Susan J Vannucci; Steven W Levison; Zinaida S Vexler; Pierre Gressens
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.